Structural Valve Deterioration in Transcatheter Aortic Bioprostheses: Diagnosis, Pathogenesis, and Treatment

IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Sankalp P. Patel DO , Santiago Garcia MD , Janarthanan Sathananthan MBChB, MPH , Gilbert H.L. Tang MD, MSc, MBA , Mazen S. Albaghdadi MD, MSc , Philippe Pibarot DVM, PhD , Robert J. Cubeddu MD
{"title":"Structural Valve Deterioration in Transcatheter Aortic Bioprostheses: Diagnosis, Pathogenesis, and Treatment","authors":"Sankalp P. Patel DO ,&nbsp;Santiago Garcia MD ,&nbsp;Janarthanan Sathananthan MBChB, MPH ,&nbsp;Gilbert H.L. Tang MD, MSc, MBA ,&nbsp;Mazen S. Albaghdadi MD, MSc ,&nbsp;Philippe Pibarot DVM, PhD ,&nbsp;Robert J. Cubeddu MD","doi":"10.1016/j.shj.2022.100155","DOIUrl":null,"url":null,"abstract":"<div><p>Transcatheter aortic valve replacement has emerged as the preferred treatment modality in most patients with severe aortic stenosis. With its global adoption and broader application in younger and healthier patients, the issue of transcatheter bioprosthetic valve degeneration and its impact on valve durability continues to earn clinical relevance. Differences in the pathophysiologic processes that separate native from transcatheter heart valve deterioration remain poorly understood. When compared to surgical aortic bioprostheses, the mechanisms of valve degeneration are similar in transcatheter heart valves, with meaningful differences most noticeably found between the individual constructs of their design. Recognizing the clinical and hemodynamic presentation of structural valve degeneration remains paramount. The recently revised consensus guidelines that incorporate the integration of advanced multimodality imaging with invasive hemodynamics represent a major step forward in our ability to accurately diagnose bioprosthetic valve degeneration, and to identify differences in durability patterns, and to establish treatment recommendations for the lifetime management of patients with aortic stenosis. Parallel efforts to unmask the biomolecular differences in atherosclerotic plaque burden, valve calcification, and thrombotic diathesis, including host immunocompetence, between the different available bioprostheses, will further advance the role of emerging valve tissue technologies to improve durability. As with surgical heart valves, the optimal treatment options for redo-transcatheter aortic valve replacement and surgical explant remain poorly understood. Ongoing translational research in bench testing coupled with prospectively designed core lab-adjudicated clinical trials are much needed. This report provides a contemporary overview of transcatheter structural valve degeneration, including evolving concepts in its pathogenesis, diagnosis, and treatment.</p></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"7 3","pages":"Article 100155"},"PeriodicalIF":1.4000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236800/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Structural Heart","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2474870622019819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 1

Abstract

Transcatheter aortic valve replacement has emerged as the preferred treatment modality in most patients with severe aortic stenosis. With its global adoption and broader application in younger and healthier patients, the issue of transcatheter bioprosthetic valve degeneration and its impact on valve durability continues to earn clinical relevance. Differences in the pathophysiologic processes that separate native from transcatheter heart valve deterioration remain poorly understood. When compared to surgical aortic bioprostheses, the mechanisms of valve degeneration are similar in transcatheter heart valves, with meaningful differences most noticeably found between the individual constructs of their design. Recognizing the clinical and hemodynamic presentation of structural valve degeneration remains paramount. The recently revised consensus guidelines that incorporate the integration of advanced multimodality imaging with invasive hemodynamics represent a major step forward in our ability to accurately diagnose bioprosthetic valve degeneration, and to identify differences in durability patterns, and to establish treatment recommendations for the lifetime management of patients with aortic stenosis. Parallel efforts to unmask the biomolecular differences in atherosclerotic plaque burden, valve calcification, and thrombotic diathesis, including host immunocompetence, between the different available bioprostheses, will further advance the role of emerging valve tissue technologies to improve durability. As with surgical heart valves, the optimal treatment options for redo-transcatheter aortic valve replacement and surgical explant remain poorly understood. Ongoing translational research in bench testing coupled with prospectively designed core lab-adjudicated clinical trials are much needed. This report provides a contemporary overview of transcatheter structural valve degeneration, including evolving concepts in its pathogenesis, diagnosis, and treatment.

Abstract Image

Abstract Image

Abstract Image

经导管主动脉生物假体的结构性瓣膜恶化:诊断、发病机制和治疗
经导管主动脉瓣置换术已成为大多数严重主动脉狭窄患者的首选治疗方式。随着其在全球的采用和在更年轻、更健康的患者中的广泛应用,经导管生物瓣膜退化及其对瓣膜耐久性的影响继续具有临床意义。将天然心脏瓣膜恶化与经导管心脏瓣膜恶化区分开来的病理生理过程的差异仍知之甚少。与外科主动脉生物瓣膜相比,经导管心脏瓣膜的瓣膜退化机制相似,在其设计的单个结构之间发现了最显著的有意义的差异。认识结构性瓣膜变性的临床和血液动力学表现仍然至关重要。最近修订的共识指南将先进的多模态成像与有创血流动力学相结合,这标志着我们在准确诊断生物瓣膜退化、识别耐久性模式差异以及为主动脉瓣狭窄患者的终身管理制定治疗建议方面迈出了重要一步。同时努力揭示不同可用生物瓣膜在动脉粥样硬化斑块负荷、瓣膜钙化和血栓形成素质(包括宿主免疫能力)方面的生物分子差异,将进一步推进新兴瓣膜组织技术在提高耐用性方面的作用。与外科心脏瓣膜一样,对再次经导管主动脉瓣置换术和外科移植物的最佳治疗方案仍知之甚少。非常需要在台架测试中进行持续的转化研究,再加上前瞻性设计的核心实验室裁决的临床试验。本报告提供了经导管结构瓣膜变性的当代综述,包括其发病机制、诊断和治疗方面的概念演变。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Structural Heart
Structural Heart Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.60
自引率
0.00%
发文量
81
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信